- Ardena has launched a 2,500+ sq ft GLP bioanalytical laboratory in Somerset, New Jersey, to support preclinical and clinical studies.
- The facility expands Ardena’s North American capabilities and strengthens its global CDMO and CRO bioanalytical network.
Ardena has announced that its new GLP bioanalytical laboratory in Somerset, New Jersey, is now operational and supporting client studies. The facility expands the company’s CDMO and bioanalytical CRO capabilities in North America and provides local access to bioanalytical services for biopharma companies.
The 2,500+ sq ft laboratory is equipped with controlled sample storage, LC-MS/MS systems, and immunochemistry platforms. These technologies support quantitative analysis for both preclinical and clinical studies, covering small and large molecules across multiple therapeutic modalities.
The new laboratory strengthens Ardena’s global bioanalytical network and is intended to enable closer collaboration with clients in North America. It also complements the company’s existing operations in Europe, supporting coordinated delivery of services across regions.
The Somerset site, which Ardena acquired in 2025, includes an FDA-approved facility for advanced drug product manufacturing supporting clinical development and commercial supply. The company stated that the combined infrastructure supports precision medicine development across both continents.
“The new bioanalytical laboratory complements our established teams in Europe and strengthens our capacity to support complex therapeutic modalities, including antibody-drug conjugates and other drug conjugates, as well as biomarker analysis, in both regions.”
Gunnar Flik, Division Head of Bioanalytical Services at Ardena
